Quimioterapia antineoplásica frente al cáncer de mama en mujeres embarazadas: Prevención de Extravasaciones

Puente García, Raúl de la; Díez Láiz, Raquel; Sahagún Prieto, Ana; Fernández Martínez, Mª Nélida; Diez Liébana, Mª José; Sierra Vega, Matilde; García Viéitez, Juan José; López Cadenas, Cristina.
Rev. Rol enferm ; 46(5): 282-290, may. 2023. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-220387

Documentos relacionados

  1. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
  2. Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study.
  3. Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
  4. Construction and Analysis of a Mitochondrial Metabolism-Related Prognostic Model for Breast Cancer to Evaluate Survival and Immunotherapy.
  5. A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old.
  6. Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
  7. [Nine Cases of Pregnancy and Delivery after Breast Cancer].
  8. Impact of body mass index on survival in women receiving chemotherapy for early breast cancer.
  9. Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC).
  10. No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country.